Physician profile
Eric A Barr
NPI 1548258098
$10,530.97
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,627 · 2020: $2,560 · 2021: $1,594 · 2022: $1,605 · 2023: $1,871 · 2024: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Education: $70.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.94 |
| Education | $70.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,692.81 | 2019-2020 | |
| Abbvie INC. | $1,127.17 | 2019-2024 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $957.62 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $918.44 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.94 | 2019-2023 | Jardiance, Stiolto Respimat, Synjardy |
| Glaxosmithkline, LLC. | $763.57 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $581.87 | 2019-2024 | |
| Lilly USA, LLC | $340.86 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $225.10 | 2019-2023 | Belsomra, Verquvo |
| Sanofi-Aventis U.S. LLC | $210.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $154.02 | 2019-2023 | Xarelto |
| Amgen INC. | $147.83 | 2019-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.04 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $128.02 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $126.96 | 2019-2024 | Austedo Xr |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.